Thermo Fisher Scientific Opens cGMP Plasmid DNA Manufacturing Facility in Carlsbad, California

 
 

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif. enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.

 

"Demand for commercial plasmid DNA is outpacing supply as the development of transformative gene therapies and vaccines accelerates globally," said Marc N. Casper , chairman, president and chief executive officer, Thermo Fisher Scientific. "Investments in state-of-the-art manufacturing such as this ensure that our customers have reliable access to the high-quality materials and capabilities that have become vital for the production of these new lifesaving medicines and the patients in need."

 

The 67,000-square-foot facility, located on Thermo Fisher's   Carlsbad campus, is part of an investment strategy to ensure customers can reliably meet growing global demand for cell and gene therapies and vaccines. With its fully integrated development, supply chain and manufacturing capabilities, which include viral vector services in Cambridge, Lexington and Plainville, Mass.. Alachua, Fla. and Gosselies and Seneffe, Belgium ; a new cell therapy manufacturing facility in Princeton, N.J.; and a new cryocenter in Weil am Rhein, Germany to support clinical trials, Thermo Fisher customers can quickly progress from discovery to clinical to patient impact.

 

Plasmid DNA is increasingly used as a therapeutic agent in gene therapies and certain vaccines. Its advantages, including weak immunogenicity, increased safety and ease of manufacture, have dramatically increased demand for materials and manufacturing capacity globally.

 

The expansion in Carlsbad also benefits the growing life sciences ecosystem in California , and Thermo Fisher will add more than 150 new roles as manufacturing scales. To celebrate the opening of the new facility, Thermo Fisher hosted a ribbon-cutting ceremony today with local government officials including U.S. Representatives Mike Levin and Scott Peters and Carlsbad City Mayor Matt Hall .

 

"This expansion in Carlsbad is exciting, bringing new jobs and revenue to our district, while also advancing San Diego County's reputation as a hub for innovation," said Rep. Levin, CA-49. "Their work helps tackle many of the world's greatest challenges and builds healthier, more sustainable communities."

 

Rep. Peters, CA-52 said, "I'm thrilled that this expansion will add jobs, advance medical services manufacturing capabilities in San Diego and California and further bolster our regions' leadership in scientific innovation."

 

"We're pleased that Thermo Fisher continues to expand its footprint in Carlsbad , and their investment will contribute greatly to our community's economic development and our reputation as a home to innovators who are improving health and medicine globally," said Carlsbad Mayor Matt Hall.

 

To learn more about Thermo Fisher's new cGMP Plasmid DNA manufacturing facility, please visit www.thermofisher.com/patheon .  Open positions can be found at jobs.thermofisher.com .

 

  About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

 
 

  Investments in state-of-the-art manufacturing ensure that Thermo Fisher cell and gene therapy customers have reliable access to the high-quality materials and capabilities that have become vital for the production of new therapies and vaccines. 

 
 

Media Contact Information:
  Ron O'Brien  
Thermo Fisher Scientific
 
Phone: 781-622-1242
E-mail:    ron.obrien@thermofisher.com  

 

Investor Contact Information:
  Rafael Tejada  
Thermo Fisher Scientific
 
Phone:  781-622-1356
E-mail:    rafael.tejada@thermofisher.com  

 
 

  Thermo Fisher Scientific logo (PRNewsfoto/Thermo Fisher Scientific) 

 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-opens-cgmp-plasmid-dna-manufacturing-facility-in-carlsbad-california-301334287.html  

 

SOURCE Thermo Fisher Scientific

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×